London
Zurich
Boston
Sales and Divestitures
Sales and Divestitures
- Sale mandates
- Recapitalisations
- Shareholder restructurings
- Business reviews
Mergers and Acquisitions
Mergers and Acquisitions
- Acquisition mandates
- Leveraged and management buyouts
- Post deal strategy and implementation
- Mergers mandates
Private Placements
Private Placements
- Private equity
- Private debt and mezzanine
- Refinancing
Advisory Services
Advisory Services
- Corporate development
- Intellectual property management
- Strategic and capital market alternatives
- Acquisition
About
HCP is a healthcare and life sciences investment banking firm created to advise small and middle-market healthcare companies. Its partners have completed more than 100 transactions in the healthcare sector with a value in excess of $1 billion. The majority of transactions ranged in size from $10-100m. HCP advises healthcare and life sciences companies in identifying and structuring value-enhancing transactions primarily between the US and Europe. It focuses on business and assets divestitures, private equity and venture capital fund raising. HCP’s competitive advantages include:
- a focused healthcare/life sciences seasoned professional trans-Atlantic team
- leveraging our European and US investment bankers’ transaction experience
- drawing upon our experience as senior members of European and US healthcare and life sciences companies to advise clients on corporate or project strategy
- accepting equity participation in lieu of cash for advisory fees
HCP focuses on the life sciences, pharmaceutical, medtech, and healthcare services.
transactions
HCP advises small and middle-market healthcare companies. Its partners have completed more than 100 transactions in the healthcare sector with a value in excess of $1bn. HCP advises healthcare companies in identifying and structuring value-enhancing transactions primarily between the US and Europe. It focuses on business and assets divestures, private equity and venture capital fund raising.
Sebia - Secondary Buy- Out of French Diagnostics Company
Advisor to the Management team of French diagnostics manufacturer Sebia on the secondary buyout by Montagu Private Equity from Astorg Partners
Renal Services – Sale of the company
Advisor to the shareholders of UK dialysis company Renal Services on its sale to DaVita International
CathNet Sciences SA – Sale of a Medtech company controlled by Boston Scientific
Advisers to Boston Scientific and management on the sale of ICV company CathNet Sciences SA
Nagor - Sale of UK breast and Silicone Implant company Nagor
Advisor to private British Silicone implant manufacturer Nagor on sale to US public company Medicor Limited
Lantor UK - Sale of Wound Care Company
Advisor to private equity fund Horizon Partners Limited on the sale of Lantor UK to BFF Technical Fabrics
Biosil - Sale of UK breast and Silicone Implant company Biosil
Advisor to private British Silicone implant manufacturer Biosil on sale to US public company Medicor Limited
Minvasys - Sale of French Cardiovascular Devices Manufacturer
Advisor to French private company Minvasys focusing on the design, development and manufacturing of cardiovascular stents on the sale of its core business to a strategic buyer
Labnova – Sale of specialty chemical company
Advisor to the shareholders of a private Italian chemical reagents manufacturer to Japanese medtech company Nihon Kohden
Arthesys - Sale of Non-Core Assets by French IVC Company
Advisor to private French Interventional Cardiology company Arthesys on disposal of Non-Core Assets
Lipoxen – identified and structured pre-IPO investment
Advisor to a Russian investment group – identified and structured the investment in a UK biotech company prior to IPO
IGNA - Sale of France Largest Genetic Testing Laboratory
Advisor to private equity funds Rothschild and Matigonon on the sale of IGNA to a strategic buyer
OrthoRehab - Sale of US Orthopedic Products company OrthoRehab
Advisor to the shareholders of private US orthopedic company Ortho Rehab Inc. on sale to German company Otto Bock Healthcare LP
Medicom - Sale of Bang & Olufsen Drug Delivery Devices Subsidiary
Advisor to Bang & Olufsen on the sale of a non-core medical subsidiary to a private equity fund
Stirling Square Capital Parnters - MBO of European Dialysis Provider
Advisor to private equity fund Stirling Square Capital Partners on the MBO of Baxter's Dialysis Services division
Cannaray – Private placement of equity and debt
Advisor to UK cannabis company Cannaray on private placements of equity and debt
Santersus – Private placement of equity and debt
Advisor to Swiss therapeutic company Santersus on private placements of equity and debt
Area of expertise
Management
Our competitive advantage lies in having senior HCP members and global industry experts as project leaders. Our senior team members maintain day-to-day involvement with the client and actively direct our analyst teams.
Our trans-Atlantic alliance allows us to customize project strategies by incorporating critical market, regulatory and other considerations into the project. In many cases after completing a transaction, our senior members maintain an active dialogue and participation with the client. This participation has included continuing advisory work for the existing business, identifying new opportunities for the client and participating as a shareholder in the client’s business.
Unlike other investment banking firms, we, in many instances, take equity stakes in our clients’ companies instead of cash payments for our fees. As a shareholder and/or board member, we continue to provide expert financial and strategic advice to the client company.
Contact info
Healthcare Capital Partners Limited
-
17 Ives Street
London SW3 2ND
United Kingdom